Intriguingly, in an in vivo ovarian cancer xenograft model, CAFs were found to efficiently promote the metastatic colonization of cancer cells in the intraperitoneal microenvironment, whereas the EGFR tyrosine-kinase inhibitor gefitinib inhibited the metastatic spread of ovarian cancer. Here, EGFR is linked to ovarian carcinoma.